Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
Americas
If law firms begin to fear the political repercussions of doing their jobs, the ‘whole system could unravel’. Muireann Bolger finds a concerned profession looking for leaders to oppose ‘open retribution’.   13 March 2025
Fed Circ removes Apple import watch ban threat
Americas
Appeals court affirms PTAB’s invalidation of three heart monitoring patents | Decision voids limited exclusion order that temporarily halted Apple watch imports into the US.   11 March 2025
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group  counsels explore ‘empowerment’
Americas
Senior legal voices from the world’s biggest companies share perspective on International Women’s Day theme | Action is key as gender parity remains a distant goal–forecasted to take at least 134 years.   6 March 2025
Pharma
Federal Circuit says only patents claiming the active ingredient of a drug are eligible for listing | Injunction against Teva temporarily paused in January pending the appeal court’s decision to review.   4 March 2025
Americas
Market leader settles patent disputes with generic drug makers, blocking the release of versions of two key products | More than 80% of HIV patients in the US use Gilead’s treatments.   20 February 2025
Americas
Nominations open as D&I values face growing backlash on both sides of the pond | Research shows equality efforts result in creativity and productivity | Categories include Influential Women in IP, Diversity Champions, and Future Champions.   13 February 2025
Americas
Popular fitness tracker device accused of infringing patents owned by Omni MedSci | Plaintiff previously sued Apple over Apple Watch.   6 February 2025
Americas
Complex legal battle concerns ‘skinny label’ strategy used by generic drug makers, prompting a $235 million award | Pharma giant looks for enhanced damages due to ‘wilful infringement’, while opponent wants another trial.   29 January 2025
Careers
New recruit brings expertise in developing and prosecuting complex patent portfolios for small molecule drug products | Partner joins from New York law firm Fenwick & West.   24 January 2025
Americas
New president says repeal is first of “many steps the US federal government will take to repair our institutions and our economy” | Defunct order aimed to lower drug costs and place caps on essential medications | Big Pharma argues higher drug prices are necessary to fund R&D for new therapies.   21 January 2025

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.